Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale Schenk

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 9, 2013
Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptideNicolaas A Verwey, Jeroen J M Hoozemans, Carsten Korth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2011
Revision of the criteria for Alzheimer’s disease: A symposiumSteven T DeKosky, Maria C Carrillo, Creighton Phelps, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2003
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathologyFrédérique Bard, Robin Barbour, Catherine Cannon, et al.
The Journal of Biological Chemistry|July 19, 2006
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body diseaseJohn P Anderson, Donald E Walker, Jason M Goldstein, et al.
The Journal of Biological Chemistry|November 20, 2009
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer diseaseGuriqbal S Basi, Hadar Feinberg, Farshid Oshidari, et al.
Plos One|February 20, 2014
Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's diseaseGergely Tóth, Shyra J Gardai, Wagner Zago, et al.
Scientific Reports|November 20, 2019
Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated DysfunctionsGergely Tóth, Thomas Neumann, Amandine Berthet, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
A roadmap for the prevention of dementia: the inaugural Leon Thal SymposiumZaven S Khachaturian, Ronald C Petersen, Serge Gauthier, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 11, 2012
Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational SummitMary D Naylor, Jason H Karlawish, Steven E Arnold, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 9, 2013
Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptideNicolaas A Verwey, Jeroen J M Hoozemans, Carsten Korth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2011
Revision of the criteria for Alzheimer’s disease: A symposiumSteven T DeKosky, Maria C Carrillo, Creighton Phelps, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2003
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathologyFrédérique Bard, Robin Barbour, Catherine Cannon, et al.
The Journal of Biological Chemistry|July 19, 2006
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body diseaseJohn P Anderson, Donald E Walker, Jason M Goldstein, et al.
The Journal of Biological Chemistry|November 20, 2009
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer diseaseGuriqbal S Basi, Hadar Feinberg, Farshid Oshidari, et al.
Plos One|February 20, 2014
Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's diseaseGergely Tóth, Shyra J Gardai, Wagner Zago, et al.
Scientific Reports|November 20, 2019
Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated DysfunctionsGergely Tóth, Thomas Neumann, Amandine Berthet, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
A roadmap for the prevention of dementia: the inaugural Leon Thal SymposiumZaven S Khachaturian, Ronald C Petersen, Serge Gauthier, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 11, 2012
Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational SummitMary D Naylor, Jason H Karlawish, Steven E Arnold, et al.
Pageof 7